Apidra, a rapid-acting insulin, received FDA approval in 2004 [1]. It is used to control high blood sugar in adults and children who have diabetes [2].
When did Apidra's patent protection end?
Information regarding the specific patent expiration dates for Apidra is not readily available through the provided context. Drug patent information, including expiration timelines, can be accessed through resources like DrugPatentWatch.com [3].
How does Apidra work?
Apidra is a rapid-acting insulin analog that works by lowering blood sugar levels. It is absorbed quickly into the bloodstream and begins to lower blood sugar within 10 to 20 minutes of injection. Its peak effect occurs between 1 and 2 hours, and its duration of action is typically 3 to 5 hours [2]. It is designed to mimic the body's natural insulin response after meals [4].
What are the key differences between Apidra and other insulins?
Apidra is characterized by its rapid onset and relatively short duration of action, making it suitable for mealtime control of blood glucose. Other insulin types, such as long-acting insulins, are designed to provide background insulin coverage over a longer period. The specific choice of insulin depends on an individual's diabetes management needs [4].
What are the approved uses and patient populations for Apidra?
Apidra is approved for the treatment of high blood sugar in adults and children with diabetes. It can be used in conjunction with long-acting insulin or as part of a basal-bolus insulin regimen [2].
What are the potential side effects of Apidra?
The most common side effect associated with Apidra, like other insulins, is hypoglycemia, or low blood sugar. Other potential side effects include allergic reactions, injection site reactions, and lipodystrophy (changes in fat tissue at injection sites) [2].
Who manufactures Apidra?
Apidra is manufactured by Sanofi [5].
What is the clinical data supporting Apidra's approval?
Clinical trials leading to Apidra's approval demonstrated its efficacy in lowering blood glucose levels in patients with type 1 and type 2 diabetes. These studies assessed its pharmacokinetic and pharmacodynamic profiles, comparing it to other insulin therapies [2, 4].
What are the current treatment guidelines involving rapid-acting insulins like Apidra?
Current diabetes management guidelines generally recommend the use of rapid-acting insulin analogs, such as insulin glulisine (Apidra), for prandial (mealtime) insulin therapy in both type 1 and type 2 diabetes. These insulins are favored for their ability to more closely match the body's natural insulin response to food intake [4].
What are the regulatory considerations for insulin products like Apidra?
Insulin products are subject to stringent regulatory review by agencies like the FDA to ensure their safety, efficacy, and quality. This includes evaluations of manufacturing processes, clinical trial data, and post-market surveillance [1].
What are the future outlooks for rapid-acting insulins?
Research and development in diabetes care continue to focus on improving insulin formulations, delivery devices, and combination therapies to enhance glucose control and patient convenience. This includes exploring ultra-rapid acting insulins and closed-loop insulin delivery systems [4].
What are the patient concerns regarding insulin therapy?
Patients often express concerns about the burden of daily injections, potential for hypoglycemia, weight gain, and the cost of insulin therapy. Effective patient education and support are crucial for managing these challenges [4].
---
Sources:
1. U.S. Food & Drug Administration. (2004). FDA Approves Apidra (insulin glulisine) Injection.
2. Apidra.com. About Apidra®. Package Insert.
3. DrugPatentWatch.com.
4. American Diabetes Association. (2019). Standards of Medical Care in Diabetes—2019 abridged for primary care physicians. Diabetes Care, 42(Supplement_1), S1-S11.
5. Sanofi.